Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state

Circulation

Volumn 101, Issue 9, 2000, Pages 975-980

  Haffner, Steven M ^a,b   Mykkänen, Leena ^a   Festa, Andreas ^a   Burke, James P ^a   Stern, Michael P ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Blood pressure; Cholesterol; Diabetes mellitus; Insulin; Lipids

Indexed keywords

ADULT; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; BODY MASS; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0343185923     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.9.975     Document Type: Article

References (33)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979; 2:120-126.
2. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes Data Group; 1995;429-448.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
4. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-967.
5. Klein R. Kelly West Lecture 1994: hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
6. West KM, Ahuja MMS, Bennett PH, Czyzyk A, DeAcosta OM, Fuller JH, Grab B, Bragauskas V, Jarrett RJ, Kosaka K. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care. 1983; 6:361-369.
7. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
8. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:160-178.
9. Medalie JH, Papier DM, Goldbourt U, Herman JB. Major factors in the development of diabetes mellitus in 10 000 men. Arch Intern Med. 1975; 135:811-817.
10. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin dependent diabetes mellitus in a community of older adults. Am J Epidemiol. 1990;131:443-453.
11. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M. Cardiovascular disease risk factors as predictors of type II (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia. 1993;36:553-559.
12. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
13. Fagot-Campagna A, Narayan KM, Hanson RL, Imprematore G, Howard BV, Nelson RG, Pettitt DJ, Knowler WC. Plasma lipoproteins and incidence of non-insulin-dependent diabetes mellitus in Pima Indians: protective effect of HDL cholesterol in women. Atherosclerosis. 1997; 128:113-119.
14. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med. 1993;329:1988-1992.
15. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body fat distribution. Diabetes. 1990;39: 283-288.
16. Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY. Association of elevated fasting C-peptide levels and increased intra-abdominal fat distribution with development of NIDDM in Japanese American men. Diabetes. 1990;39:104-111.
17. Sicree RA, Zimmet PZ, King HOM, Coventry JS. Plasma insulin response among Nauruans: prediction of deterioration in glucose tolerance over 6 years. Diabetes. 1987;36:179-186.
18. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, Takaku F, Kosaka K. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26:44-49.
19. Chen KW, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, Fujimoto WY. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM: 5 year follow-up of initially non-diabetic Japanese American men. Diabetes Care. 1995;18:747-753.
20. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of non-insulin dependent diabetes mellitus. Diabetes. 1995; 44:1386-1391.
21. Lundgren H, Bengtsson C, Blohme G, Lapidus L, Waldenstrom J. Fasting serum insulin concentrations and early insulin response as risk determinants for developing diabetes. Diabet Med. 1990;7:407-413.
22. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1596-1607.
23. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 1997;193: 152-162.
24. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
25. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group. The STOP-NIDDM trial: an international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care. 1998;21: 1720-1725.
26. Haffner SM, Stern MP, Hazuda HP, Pugh J, Patterson J. Hyperinsulinemia in a population at high risk for non-insulin dependent diabetes mellitus. N Engl J Med. 1986;315:220-224.
27. World Health Organization Study Group on Diabetes Mellitus. Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization (Technical Report Series, No. 727); 1985:94-98.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor GA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
29. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
30. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YD, Sands RE, Pei D, Savage PJ, Bergman RN. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance: Insulin Resistance Atherosclerosis Study. Diabetes. 1994;43:1114-1121.
31. Philips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose and insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and secretion. Diabet Med. 1994;11:286-292.
32. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
33. Haffner SM, Miettenen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20:1087-1092.